PT - JOURNAL ARTICLE AU - Elvira Mauz AU - Lena Walther AU - Stephan Junker AU - Christina Kersjes AU - Stefan Damerow AU - Sophie Eicher AU - Heike Hölling AU - Stephan Müters AU - Diana Peitz AU - Susanne Schnitzer AU - Julia Thom TI - Time trends of mental health indicators in Germany’s adult population before and during the COVID-19 pandemic AID - 10.1101/2022.10.09.22280826 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.09.22280826 4099 - http://medrxiv.org/content/early/2022/10/10/2022.10.09.22280826.short 4100 - http://medrxiv.org/content/early/2022/10/10/2022.10.09.22280826.full AB - Background Times of crisis such as the COVID-19 pandemic are expected to compromise mental health. Despite a large number of studies, evidence on the development of mental health in general populations during the pandemic is inconclusive. One reason may be that representative data spanning the whole pandemic and allowing for comparisons to pre-pandemic data are scarce.Methods We analyzed representative data from telephone surveys of Germany’s adults: “German Health Update (GEDA)” and “COVID-19 vaccination rate monitoring in Germany (COVIMO)”. Three indicators of mental health were observed in approximately 1,000 and later 3,000 randomly sampled participants monthly until June 2022: symptoms of depression (observed since April 2019 using the PHQ-2), symptoms of anxiety (observed since March 2021 using the GAD-2) and self-rated mental health (observed since March 2021 using a single item). We produced time series graphs including estimated three-month moving means and proportions of individuals with a positive screen (PHQ/GAD-2 score ≥ 3) and of those reporting very good/excellent mental health, as well as smoothing curves. We also compared time periods between years. Analyses were stratified by sex, age, and level of education.Results While mean depressive symptom scores declined from the first wave of the pandemic to summer 2020, they increased from October 2020 and remained consistently elevated throughout 2021 with another increase between 2021 and 2022. Correspondingly, the proportion of positive screens first decreased from 11.1 % in spring/summer 2019 to 9.3 % in the same period in 2020 and then rose to 13.1 % in 2021 and to 16.9 % in 2022. While depressive symptoms increased in all subgroups at different times, developments among women, the youngest and eldest adults, and the high level of education group stand out. Furthermore, symptoms of anxiety increased while self-rated mental health decreased between 2021 and 2022.Conclusions Elevated symptom levels and reduced self-rated mental health at the end of our observation period in June 2022 call for further continuous mental health surveillance. Mental healthcare needs of the population should be monitored closely. Findings should serve to inform policymakers and clinicians of ongoing dynamics to guide health promotion, prevention, and care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Federal Ministry of Health (Grant Number: ZMI5-2519FSB402). Christina Kersjes received funding from The German Research Foundation (Project Number: 458531028).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of the Charité Universitätsmedizin Berlin gave ethical approval for this work (application number EA2/070/19).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPopulation-based data from the German health monitoring program that support the findings of this study are available from the Robert Koch Institute (RKI) but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. The data set cannot be made publicly available because informed consent from study participants did not cover public deposition of data. However, a minimal data set is archived in the Health Monitoring Research Data Centre at the RKI and can be accessed by all interested researchers. On-site access to the data set is possible at the Secure Data Centre of the RKIs Health Monitoring Research Data Centre. Requests should be submitted to the Health Monitoring Research Data Centre, Robert Koch Institute, Berlin, Germany (Email: fdz{at}rki.de). COVIMOCOVID-19 vaccination rate monitoring in GermanyCWcalendar weekGAD-2Generalized Anxiety Disorder Questionnaire (2 items)GEDAGerman Health UpdateEHISEuropean Health Interview SurveyPHQ-2/8/9Patient Health Questionnaire (2/8/9 items)RKIRobert Koch InstituteSESSocio-economic statusSRMHSelf-rated mental health